Equibles does not estimate personal net worth.
Get an email with a short summary when Cellectar Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get CLRB alertsJarrod Longcor is recorded as COO at Cellectar Biosciences, Inc. (CLRB). The newest filing on record that lists Jarrod Longcor as COO at Cellectar Biosciences, Inc. (CLRB) is dated May 28, 2026. The proxy statement of Cellectar Biosciences, Inc. reports total compensation of $1,830,000 for Jarrod Longcor in fiscal 2024, including a base salary of $500,000. Disclosed compensation is on record for 7 fiscal years. Jarrod Longcor has spoken on 10 earnings calls across 1 company, most recently for Cellectar Biosciences, Inc. on August 13, 2026. Cellectar Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cellectar Biosciences, Inc. includes James Caruso (CEO and Board Member), James V. Caruso (CEO and Board Member), Douglas J. Swirsky (Chairman and Board Member) and 7 others.
“As Jim noted, we continue to make meaningful progress across our clinical, regulatory, and development initiatives and believe SelectArt is entering an important phase of execution with multiple value-driving milestones ahead.”
“As Jim highlighted, our regulatory and clinical progress in 2025 positions us well for important advances across our pipeline programs and for a milestone-rich 2026.”
“As Jim just reviewed, we believe iopofosine I-131 has a high probability of approval in the EU, and pending the initiation of the confirmatory study, its approval in the US.”
“Earlier this year, Iopofosine I-131 was granted FDA breakthrough therapy designation for the treatment of WM. I will now focus on the FDA strategy for Iopofosine based on these outcomes.”
“I'll now review the regulatory and clinical status of iopofosine and two of our exciting earlier stage radio conjugates. The first is our alpha emitting actinium-based compound, CLR 121225, and the second is CLR 121125, our lead Auger-emitting radiotherapeutic.”
Start not stated–present
Last confirmed May 28, 2026
Proxy statement
Start not stated–2021-05-13
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
COO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Cellectar Biosciences, Inc. (CLRB) | Chief Operating Officer | $500,000 | $1,830,000 |
| 2023 | Cellectar Biosciences, Inc. (CLRB) | Chief Operating Officer | $480,000 | $1,362,560 |
| 2022 | Cellectar Biosciences, Inc. (CLRB) | Chief Operating Officer | $450,000 | $831,755 |
| 2021 | Cellectar Biosciences, Inc. (CLRB) | Chief Operating Officer | $385,037 | $891,446 |
| 2020 | Cellectar Biosciences, Inc. (CLRB) | Chief Operating Officer and Former Chief Business Officer | $353,245 | $574,507 |
| 2019 | Cellectar Biosciences, Inc. (CLRB) | Chief Business Officer | $333,250 | $539,303 |
| 2018 | Cellectar Biosciences, Inc. (CLRB) | Chief Business Officer | $325,000 | $477,888 |
